Introduction
Relapsing polychondritis was first described 80 years ago, and although much has been written about this unusual disease, there continues to be much that we do not know. Although clinical observations have been well described, some of these reflect manifestations of associated diseases. The pathogenesis remains unknown, although immune abnormalities observed over the years led us to classify it as an autoimmune disease. Some of the difficulties involved in studying this disease relate to its rarity (making it difficult to study patients with a similar phenotype), the lack of appropriate animal models, and the lack of consistent laboratory abnormalities, all of which lead to difficulty in developing a clear working hypothesis. Ongoing efforts in this direction may soon produce results. The lack of substantial populations in any one center's therapeutic studies leave us with generic approaches to treatment, as is true of many immune-mediated inflammatory diseases. With the advances in our ability to investigate molecular mechanisms of diseases, and understanding the role of genomics and proteomics, we anticipate major advances in our understanding of this "syndrome" in the near future.
Clinical features and organ-specific special investigations
Diagnostic criteria that distill the most common clinical features of relapsing polychondritis were put forth in 1976 by McAdam et al. [1] , but have since been modified. Currently, the diagnosis is usually made on the basis of chondritis in two of three sites (auricular, nasal, laryngotracheal) or one of those sites and two other features, including ocular inflammation, audiovestibular damage, or seronegative inflammatory arthritis [2,3]. A biopsy is unnecessary in most cases.
Clinical manifestations
The reader is referred to several papers that review the literature on relapsing polychondritis [4,5•]. The frequency of clinical manifestations in relapsing polychondritis is shown in Table 1 , which combines data from three large studies involving 337 patients [1,3,4]. Auricular chondritis is the most frequent and unique presenting sign, causing subacute onset of pain, redness, and swelling of the ear, sparing the lobule. Attacks often occur in a relapsing-remitting pattern and may leave a floppy pinna or cauliflower deformity. Conductive hearing loss can result from stenosis of the external auditory canal, Eustachian tube chondritis, or serous otitis media. Pre-sumed vasculitis of the internal auditory artery may result in acute sensorineural hearing loss with or without symptoms of vestibular dysfunction [6] .
Musculoskeletal manifestations
Arthritis is the second most common presenting symptom of relapsing polychondritis and it eventually affects more than 70% of patients. The arthritis of pure relapsing polychondritis is intermittent, migratory, asymmetric, seronegative, and usually nonerosive [7] . Hand and foot radiographs typically show joint space reduction and/or osteopenia [8] . Relapsing polychondritis is often described in the presence of other arthropathy-inducing diseases such as connective tissue diseases, rheumatoid arthritis, and the spondylarthropathies [5•].
Ocular manifestations
Although only approximately 18% of patients present with some evidence of ocular inflammation, this eventually develops in nearly 60%. Episcleritis and scleritis are the most common manifestations, followed by keratoconjunctivitis sicca, iritis, retinopathy, keratitis, optic neuritis, and corneal melt [9] . Inflammation external to the globe can result in orbital pseudotumor, extraocular muscle palsy, and lid edema.
Otorhinolaryngeal manifestations
Nasal chondritis is painful, affects the distal part of the nasal septum, and through recurrent episodes leads to a saddle nose deformity. Chondritis of the laryngotracheal cartilages occurs in more than half of patients, with a female preponderance, and may present with anterior neck pain, hoarseness, cough, inspiratory obstruction with choking, shortness of breath, or wheezing. Anatomically, obstruction results from edema, vocal cord palsy [10], fixed subglottic or bronchial stenoses, and/or dynamic airway collapse.
Pulmonary manifestations
Pulmonary function tests, including inspiratory and expiratory flow volume curves, should be performed in all patients with relapsing polychondritis to detect occult airway disease [11, 12] . In the presence of respiratory symptoms or pulmonary function test abnormalities, CT of the chest should be performed. Findings may include tracheal and bronchial stenoses, thickening and calcifications of the airway walls, obstructive bronchiectasis, and dynamic tracheal/bronchial collapse [13, 14] . Bronchoscopy is not routinely used because it poses a risk of respiratory decompensation to the patient, but it may help distinguish postinflammatory from active inflammatory lesions. Costochondritis and inflammation of the manubriosternal joint may also compromise respiration.
Renal manifestations
Urinalysis should be obtained with follow-up visits because approximately 22% of patients with relapsing polychondritis develop some type of renal lesion documented by microhematuria, proteinuria, or abnormal kidney biopsy [15] . Renal involvement is associated with a higher incidence of extrarenal vasculitis, arthritis, and a worse survival. Renal pathology has included mesangial expansion, IgA nephropathy [16], tubulointerstitial nephritis, and segmental necrotizing crescentic glomerulonephritis [15] . Some renal lesions may be associated with coexisting diseases such as systemic lupus erythematosus.
Dermatologic manifestations
A recent study of 200 cases of relapsing polychondritis found that 73 patients (37%) had at least one associated disease that could cause a skin condition [17] . Of the remaining 127 patients with "pure" relapsing polychondritis, 45 (35%) had dermatologic involvement during the course of follow-up. Oral aphthous ulcers were the most frequent manifestation, followed by nodules on the limbs with an erythema nodosum appearance (15%), purpura, sterile pustules, superficial phlebitis, and livedo reticularis. Limb ulcerations, urticarial papules, bluish red papules, distal necrosis, and erythema elevatum diutinum were each seen in less then 5% of patients. Although seven patients had both oral and genital aphthae in the absence of other diseases, none had uveitis and they were not classified under the "MAGIC syndrome" (mouth and genital ulcers with inflamed cartilage) [18] . Leukocytoclastic vasculitis was the most frequent biopsy diagnosis, with other causes including septal panniculitis, neutrophilic dermatoses, and thrombotic occlusion of dermal vessels. Of patients with a myelodysplastic syndrome and relapsing polychondritis, 91% had dermatologic involvement, and the mean age at first chondritis was 63 years compared with 41 years in patients without an associated disease. The coexistence of skin manifestations and relapsing polychondritis in the elderly warrants vigilance for the development of a myelodysplastic syndrome. 
Pathogenesis, laboratory studies, and histopathologic findings
The pathogenesis of relapsing polychondritis is not known. There is a significant increase in the frequency of human leukocyte antigen (HLA)-DR4 in patients, and the disease is associated negatively with HLA-DR6 [30, 44] . Oligonucleotide-based genotyping, however, failed to show any predominant HLA-DR4 subtype [44] . HLA-DQ6/8 transgenic mice develop auricular chondritis after immunization with type II collagen [45] . Antibodies to type II collagen, as well as types IX and XI have been described, but they lack sensitivity and specificity [46] [47] [48] [49] . Cell-mediated immunity is important in the pathogenesis of relapsing polychondritis [50] . Levels of macrophage inhibitory factor are significantly higher in patients than in control subjects [51] . Furthermore, one patient has been characterized with T-cell clones specific for a type II collagen epitope [52•]. Rarely, there may be a mechanical insult to cartilage such as ear piercing of the cartilaginous portion, which is temporally correlated with the development of relapsing polychondritis [53] .
Nonspecific markers of an inflammatory state may be present with active relapsing polychondritis. Other sero-logic tests are of little value, other than to suggest associated diseases. Antineutrophil cytoplasmic antibodies have been found in some patients with relapsing polychondritis [54] . These may be nonspecific or may be associated with overlap syndromes.
Histopathology of involved cartilage specimens in relapsing polychondritis reveals loss of normal cartilage basophilia with hematoxylin-eosin staining and inflammation of the perichondrium with neutrophils, eosinophils, lymphocytes, and plasma cells. Later, cartilage is replaced by granulation tissue and fibrosis [55] . Immunofluorescence studies may show the presence of immunoglobulin and C3 complement deposits along the chondrofibrous junction and in perichondral vessel walls [56] .
Differential diagnosis
Because of its rarity and attribution of symptoms to other coexistent disease, 1 or 2 years may elapse before the diagnosis is made. Auricular chondritis is relatively unique to relapsing polychondritis and eventually occurs in nearly 90% of cases. However, necrotizing external otitis resulting from Pseudomonas aeruginosa should always be considered in the patient with a unilateral inflamed ear [57] .
Various diseases can cause inflammatory or granulomatous lesions of the larynx and subglottic region, including Wegener granulomatosis, sarcoidosis, tuberculosis, amyloidosis, and rheumatoid arthritis [58, 59] . The differential diagnosis of a saddle nose deformity includes Wegener granulomatosis, relapsing polychondritis, and rarely syphilis or leprosy.
Management
Because of its rarity, treatment for relapsing polychondritis is based more on case series than on quality clinical trials. Traditional therapy is with oral corticosteroids, in doses of 10 to 20 mg daily for mild to moderate auricular and nasal chondritis or arthritis, whereas doses of 1 mg/kg/day are used for sensorineural hearing loss, vestibular symptoms, ocular involvement, respiratory compromise, and vascular and renal complications. Pulse intravenous steroids (1 g/day for 3 days) and nebulized racemic ephedrine may be helpful for acute airway obstruction, allowing tracheostomy to be performed electively instead of emergently [60, 61] .
Nonsteroidal antiinflammatory drugs may be useful for arthralgias and mild arthritis. Colchicine (0.6 mg twice daily) is of reported benefit particularly for auricular chondritis, for which its effects are noted within days [62, 63] . Dapsone (50 to 200 mg/day) may also be of use in milder disease, but side effects are common [64, 65] .
One recent report describes a child successfully treated with daily oral fetal bovine type II collagen. There was also a dramatic change in the pre-and posttreatment T-cell cytokine profile. Although little can be gleaned from this single report, the favorable side effect profile oral type II collagen makes it deserving of further study [66••] .
Methotrexate and azathioprine have been used with some success as disease-modifying and steroid-sparing agents [4, 67] . Treatment with oral (1 to 2 mg/kg/day) or pulse intravenous (0.6 g/m 2 ) cyclophosphamide is used for organ-threatening pulmonary, cardiac, or renal disease [68, 69] . Cyclosporine A, in doses of 5 to 15 mg/kg/day has helped in several cases that were refractory to other agents [70, 71] .
Several biologic therapies have been tried in relapsing polychondritis. An anti-CD4 chimeric monoclonal antibody has been successful as a salvage therapy [72] . Infliximab has been reported to induce remission in one patient [73] , but another diabetic patient with relapsing polychondritis developed severe septicemia, a parasternal abscess, and died after initiating infliximab therapy [74] . When other treatments fail, autologous stem cell transplantation may induce complete remission in relapsing polychondritis [75] .
Adjuncts to medication therapy may be required. Continuous positive airway pressure can provide symptomatic benefit, particularly at night, in patients with tracheo-and bronchomalacia [76] . Tracheostomy may be required in the setting of respiratory distress and localized subglottic involvement [77] . Metallic stent placement can provide immediate improvement in airflow dynamics, but complications plague their use [77,78•,79, 80] . In extreme cases, surgeries to splint open externally or reconstruct the airway have been tried, but results are mediocre at best [77] .
Prophylactic complete replacement of the ascending aorta with a graft that includes the aortic valve should be performed in patients with severe aortic insufficiency to limit the postoperative risk of periprosthetic leak and aneurysm formation [81] . Patients diagnosed with thoracic aneurysms should be screened for abdominal and iliac aneurysms that may be asymptomatic until they rupture [20] . Permanent pacemaker placement is indicated for complete heart block [23] .
All patients undergoing surgery should have preoperative pulmonary function tests and, if abnormal, CT of the chest to screen for airway involvement. A small endotracheal tube placed over a bronchoscope may limit traumatic intubation or respiratory decompensation. Continuous positive airway pressure can be administered if necessary. Whenever the procedure allows, intubation should be avoided, using local or regional anesthesia [82] .
Prognostic factors
Airway involvement, infection, and cardiovascular complications including vasculitis are the leading causes of death in relapsing polychondritis [3] . Factors that negatively impact survival at the time of diagnosis include old age, anemia, and laryngotracheal stricture. Saddle nose deformity, arthritis, vasculitis, and anemia may be more important variables among patients younger than 50 years of age [3]. The 10-year survival rate reported in one series from 1986 was 55%, whereas in 1998, another series found that 94% of patients were alive after 8 years [3, 4] .
Conclusion
Relapsing polychondritis is a rare autoimmune disorder diagnosed on the basis of its clinical features. Awareness of the possible manifestations, complications, and expansion of the treatment options will hopefully continue to improve the prognosis and quality of life for affected patients.
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